Clinical trial · Interventional
The Potential Role Of MicroRNA-155 And Telomerase Reverse Transcriptase In Diagnosis Of Non-Muscle Invasive Bladder Cancer And Their Pathological Correlation
NCT03591367CI-TRIAL-00041437completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
We try to assess the potential role of telomerase reverse transcriptase and MicroRNA (miR-155) in diagnosis of non-muscle-invasive bladder cancer and their correlation with stage and grade of the tumor.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
| Bladder Disease | — | UNRESOLVED | — |
| Bladder Neoplasm | Bladder Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Micro-RNA | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Human telomerase reverse transcriptase | Diagnostic Test | — | UNRESOLVED |
| MicroRNAs-155 | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Hematuria due to suspicious superficial bladder tumor
- description
- MicroRNAs-155 (miRNAs-155) and Human telomerase reverse transcriptase (hTERT)
- interventionNames
- Diagnostic Test: MicroRNAs-155
- Diagnostic Test: Human telomerase reverse transcriptase
Primary outcomes (1)
- measure
- sensitivity, specificity and positive and negative predictive values of combined MicroRNA-155 And Telomerase Reverse Transcriptase In diagnosis Of Non-Muscle Invasive Bladder Cancer
- timeFrame
- 1 year
- description
- compared by standard final pathological specimen
Secondary outcomes (1)
- measure
- correlation between serum Vit D and Non-Muscle Invasive Bladder Cancer
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Men and women 18 years or older. * Patient with hematuria suspected to be of bladder origin clinically. * Willing to be participate in the study. Exclusion Criteria: * Patient having another malignancy. * Hematuria of other causes as trauma and stones
References
Publications (0)
Data not yet available
No reference posted for this study.